TCI Peptide Therapeutics (United States)

Recent papers from TCI Peptide Therapeutics (United States)

1. Unphosphorylated tyrosines mediate PD-1 inhibition of T cell signaling condensate formationScience · 2026
2. Novel macrocyclic peptides as potent and selective inhibitors of human neutrophil serine protease 4Journal of Molecular Biology · 2026
3. Immune tolerance versus cancer surveillance: an ongoing challengeJournal for ImmunoTherapy of Cancer · 2026
4. An Immunomodulating Peptide With Potential to Counteract EndometriosisAustralian and New Zealand Journal of Obstetrics and Gynaecology · 2026
5. A Machine Learning-Enabled Venom Peptide Platform for Rapid Drug DiscoveryPharmaceuticals · 2026
6. Multiplex screening of transferrin receptor-targeted lipid nanoparticles for systemic brain delivery using DNA barcodesCell Biomaterials · 2025
7. Neuromuscular, haemodynamic, and autonomic effects of a fast-onset, long-acting, nondepolarising, carborane neuromuscular blocking agent compared to rocuronium in rats.2025
8. Horizontal Well Acid/Propped Fracturing and Production Optimization via Multiple Hydraulic Jetted Laterals2025
9. The discovery and structural basis of two distinct state-dependent inhibitors of BamANature Communications · 2024
10. Overcoming lock-in of science-policy responses to reef heatingMarine Policy · 2024
11. Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexiaJournal of Veterinary Internal Medicine · 2023
12. Identification of sodium channel toxins from marine cone snails of the subgenera Textilia and AfonsoconusCellular and Molecular Life Sciences · 2023
13. An immunomodulating peptide to counteract solar radiation-induced immunosuppression and DNA damageScientific Reports · 2023
14. Ara h 2‐specific IgE epitope‐like peptides inhibit the binding of IgE to Ara h 2 and suppress lgE‐dependent effector cell activationClinical & Experimental Allergy · 2023
15. A flexible loop in the paxillin LIM3 domain mediates direct binding to integrin β32023
16. Development of a Therapeutic Peptide for Cachexia Suggests a Platform Approach for Drug-like PeptidesACS Pharmacology & Translational Science · 2022
17. Pharmacokinetics and safety of TCMCB07, a melanocortin‐4 antagonist peptide in dogsPharmacology Research & Perspectives · 2021
18. Characterization of the cellular transport mechanisms for the anti‐cachexia candidate compound TCMCB07Journal of Cachexia Sarcopenia and Muscle · 2020
19. Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease–associated cachexiaJournal of Clinical Investigation · 2020
20. Angiotensin-(1-7) Attenuates Skeletal Muscle Fibrosis and Stiffening in a Mouse Model of Extremity Sarcoma Radiation TherapyJournal of Bone and Joint Surgery · 2016